Table 1. Characteristics of the Study Populationa.
| Variables | Mean ± SE |
|---|---|
| Male: 22 (41.5); Female: 31 (58.5) | |
| Age, y | 47.30 ± 2.39 |
| AST, UI/L | 418.09 ± 96.87 |
| ALT, UI/I | 606.42 ± 131.13 |
| ɣ-GT, UI/l | 248.92 ± 50.04 |
| Total bilirubin, mg/dL | 3.89 ± 0.8 |
| Direct bilirubin, mg/dL | 3.17 ± 0.78 |
| Alkaline phosphatase, U/I | 159.64 ± 16.47 |
| Cholinesterase, U/mL | 6.17 ± 0.42 |
| GLDH, U/I | 33.9 ± 7.56 |
| TPZ % | 86.17 ± 3.16 |
| INR | 1.13 ± 0.03 |
| aPTT (sec) | 28.43 ± 0.55 |
| Total protein, g/L | 7.42 ± 0.14 |
| Albumin, g/L | 3.91 ± 0.09 |
| Platelets, /nL | 208.79 ± 14.04 |
| Leukocytes, /nL | 6.37 ± 0.46 |
| Hemoglobin, g/dL | 13.35 ± 0.27 |
| Cholesterol, mg/dL | 209.17 ± 19.8 |
| LDL, mg/dL | 136.56 ± 20.64 |
| HDL, mg/dL | 38.40 ± 8.96 |
| Triglycerides, mg/dL | 126.17 ± 13.12 |
| CRP, mg/dL | 8.38±1.63 |
| Immunglobulin, G, g/L | 18.44 ± 1.52 |
| Fiibrosis stage: F1/F2/F3/F4, No. (%) | 9 (17) / 15 (28.25)/ 14 (26.5) / 15 (28.25) |
| Inflammatory activity: A0-1/A2/A3/A4, No. (%) | 21 (41.5) / 9 (17) / 9 (17) / 13 (24.5) |
aF, fiibrosis stage; A, inflammatory activity.